Compare GRFS & MKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRFS | MKTX |
|---|---|---|
| Founded | 1940 | 2000 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.5B |
| IPO Year | 2006 | 2004 |
| Metric | GRFS | MKTX |
|---|---|---|
| Price | $8.87 | $175.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $10.15 | ★ $204.91 |
| AVG Volume (30 Days) | 485.7K | ★ 698.5K |
| Earning Date | 07-28-2022 | 02-06-2026 |
| Dividend Yield | 1.60% | ★ 1.73% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.64 | ★ 5.87 |
| Revenue | ★ $8,821,017,248.00 | $839,263,000.00 |
| Revenue This Year | $5.36 | $6.09 |
| Revenue Next Year | $5.15 | $8.03 |
| P/E Ratio | ★ $17.46 | $29.99 |
| Revenue Growth | ★ 7.31 | 3.37 |
| 52 Week Low | $6.19 | $156.17 |
| 52 Week High | $11.14 | $232.84 |
| Indicator | GRFS | MKTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 50.95 |
| Support Level | $8.79 | $167.48 |
| Resistance Level | $9.40 | $173.55 |
| Average True Range (ATR) | 0.24 | 3.51 |
| MACD | -0.05 | -0.91 |
| Stochastic Oscillator | 12.18 | 47.50 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.